Skip to content

Effect of traditional Chinese medicine on early renal injury in patients with chronic heart failure

Clinical study on the effect of invigorating spleen and warming kidney on renal tubular injury in patients with chronic heart failure

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004621
Enrollment
Unknown
Registered
2021-03-24
Start date
2021-04-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medicine Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age from 30 to 80, gender unlimited; (2) It meets the diagnostic criteria for CHF; (3) Urine N-acetyl-ß-D-glucosaminosidase (NAG) > 12U/L, and estimated glomerular filtration rate (EGFR) BBB> mL /min/1.73m2; (4) It meets the diagnostic criteria of the syndrome of insufficiency of spleen and Yang; (5) the cardiac function class (NYHA) II - III; (6) Signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Heart failure caused by valvular heart disease, congenital heart disease, myocarditis, cardiomyopathy, etc.; (2) People who have been diagnosed with kidney disease; (3) Severe arrhythmias, including frequent premature ventricular beats, grade II type II atrioventricular block, grade III atrioventricular block, and cardiogenic shock; (4) Patients with severe hypertension and poor medication control (SBP >= 180mmHg and/or Diastolic blood pressure >= 110mmHg); (5) Patients with severe liver function abnormalities (ALT or AST reaching more than 3 times the upper limit of normal value), endocrine diseases, malignant tumors and autoimmune diseases; (6) Pregnant or lactating women; (7) People with allergic constitution and drug components in this study; (8) Participating in other clinical trials or participating in clinical trials of other drugs for less than one month.

Design outcomes

Primary

MeasureTime frame
NAG;

Secondary

MeasureTime frame
KIM-1;IgG;IGFBP7;LVEF;BUN;RBP;mALB;ß2-MG;a1-MG;Tf;Scr;NGAL;NT-proBNP;TIMP-2;

Countries

China

Contacts

Public ContactSong Qingqiao

Guang'anmen Hospital, China Academy of Chinese Medicine Science

sqqbj@126.com+86 13911873540

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026